10x Genomics Stock Today

TXG Stock  USD 37.53  0.64  1.73%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 19

 
100  
 
Zero
Low
10X Genomics is trading at 37.53 as of the 29th of March 2024. This is a 1.73 percent increase since the beginning of the trading day. The stock's lowest day price was 36.95. 10X Genomics has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for 10X Genomics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of February 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of September 2019
Category
Healthcare
Classification
Health Care
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. The company has 105.11 M outstanding shares of which 8.58 M shares are at this time shorted by investors with about 6.1 days to cover. More on 10X Genomics

Moving together with 10X Stock

  0.66MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.83MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against 10X Stock

  0.82MDWD Mediwound Downward RallyPairCorr
  0.6CLVRW Clever Leaves HoldingsPairCorr
  0.56YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.53EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.53FGEN FibroGen Financial Report 13th of May 2024 PairCorr
  0.5MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
  0.48A Agilent Technologies Earnings Call TodayPairCorr

10X Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. 10X Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding 10X Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Thematic IdeaMeasuring and Control Equipment (View all Themes)
Business ConcentrationLife Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Measuring and Control Equipment, Health Care, Life Sciences Tools & Services, Health Information Services, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering 10X Genomics report their recommendations after researching 10X Genomics' financial statements, talking to executives and customers, or listening in on 10X Genomics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering 10X Genomics. The 10X consensus assessment is calculated by taking the average forecast from all of the analysts covering 10X Genomics.
Financial Strength
Based on the key indicators related to 10X Genomics' liquidity, profitability, solvency, and operating efficiency, 10X Genomics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of 10X Genomics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.70.6411
Significantly Up
Slightly volatile
Gross Profit Margin0.860.6615
Significantly Up
Slightly volatile
Total Current Liabilities94.9 M127.2 M
Way Down
Slightly volatile
Non Current Liabilities Total108.9 M96.9 M
Moderately Up
Slightly volatile
Total Assets746.1 M965.1 M
Significantly Down
Slightly volatile
Total Current Assets535.6 M596 M
Moderately Down
Slightly volatile
10X Genomics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to 10X Genomics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 10X Genomics' financial leverage. It provides some insight into what part of 10X Genomics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on 10X Genomics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how 10X Genomics deploys its capital and how much of that capital is borrowed.
Liquidity
10X Genomics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 95.37 M in debt with debt to equity (D/E) ratio of 0.13, which may show that the company is not taking advantage of profits from borrowing. 10X Genomics has a current ratio of 5.54, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist 10X Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, 10X Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like 10X Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for 10X to invest in growth at high rates of return. When we think about 10X Genomics' use of debt, we should always consider it together with cash and equity.

Investments

91.58 Million
10X Genomics (TXG) is traded on NASDAQ Exchange in USA. It is located in 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260 and employs 1,259 people. 10X Genomics is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 4.4 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate 10X Genomics's market, we take the total number of its shares issued and multiply it by 10X Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. 10X Genomics runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 105.11 M outstanding shares of which 8.58 M shares are at this time shorted by investors with about 6.1 days to cover. 10X Genomics has about 499.73 M in cash with (15.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39.
Check 10X Genomics Probability Of Bankruptcy
Ownership Allocation
10X Genomics holds a total of 105.11 Million outstanding shares. The majority of 10X Genomics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 10X Genomics to benefit from reduced commissions. Hence, institutional investors are subject to a different set of regulations than regular investors in 10X Genomics. Please pay attention to any change in the institutional holdings of 10X Genomics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check 10X Ownership Details

10X Stock Price Odds Analysis

In reference to a normal probability distribution, the odds of 10X Genomics jumping above the current price in 90 days from now is about 90.31%. The 10X Genomics probability density function shows the probability of 10X Genomics stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.913. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, 10X Genomics will likely underperform. Additionally, 10X Genomics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 37.53HorizonTargetOdds Above 37.53
9.64%90 days
 37.53 
90.31%
Based on a normal probability distribution, the odds of 10X Genomics to move above the current price in 90 days from now is about 90.31 (This 10X Genomics probability density function shows the probability of 10X Stock to fall within a particular range of prices over 90 days) .

10X Stock Institutional Holders

Institutional Holdings refers to the ownership stake in 10X Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 10X Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 10X Genomics' value.
InstituionRecorded OnShares
Sumitomo Mitsui Trust Holdings Inc2023-12-31
2.3 M
Venrock Management Vi Llc2023-12-31
2.1 M
Geode Capital Management, Llc2023-12-31
1.6 M
State Street Corporation2023-12-31
1.6 M
Rtw Investments, Llc2023-12-31
1.5 M
Generation Investment Management Llp2023-12-31
1.5 M
Jpmorgan Chase & Co2023-12-31
1.5 M
Bp Wealth Management, Llc2023-12-31
1.4 M
Point72 Asset Management, L.p.2023-09-30
1.3 M
Fmr Inc2023-12-31
12.8 M
Vanguard Group Inc2023-12-31
M
View 10X Genomics Diagnostics

10X Genomics Historical Income Statement

10X Genomics Income Statement is one of the three primary financial statements used for reporting 10X's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of 10X Genomics revenue and expense. 10X Genomics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, 10X Genomics' Depreciation And Amortization is most likely to increase significantly in the upcoming years. The 10X Genomics' current Cost Of Revenue is estimated to increase to about 219.9 M, while Interest Expense is projected to decrease to roughly 31.4 K. View More Fundamentals

10X Stock Against Markets

Picking the right benchmark for 10X Genomics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in 10X Genomics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for 10X Genomics is critical whether you are bullish or bearish towards 10X Genomics at a given time. Please also check how 10X Genomics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in 10X Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

10X Genomics Corporate Management

Elected by the shareholders, the 10X Genomics' board of directors comprises two types of representatives: 10X Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X Genomics' management team and ensure that shareholders' interests are well served. 10X Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
James WilburChief OfficerProfile
Ruth BackerChief OfficerProfile
Florian BaumgartnerSenior ManagerProfile
Jonathan SchimmelVP OperationsProfile
Benjamin HindsonPresident, CoFounderProfile
Eric EsqChief OfficerProfile

How to buy 10X Stock?

Before investing in 10X Genomics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in 10X Genomics. To buy 10X Genomics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of 10X Genomics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase 10X Genomics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located 10X Genomics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased 10X Genomics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as 10X Genomics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy 10X Stock please use our How to Invest in 10X Genomics guide.

Already Invested in 10X Genomics?

The danger of trading 10X Genomics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of 10X Genomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than 10X Genomics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile 10X Genomics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for 10X Stock analysis

When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Is 10X Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.18)
Revenue Per Share
5.281
Quarterly Revenue Growth
0.178
Return On Assets
(0.12)
Return On Equity
(0.33)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.